share_log

Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate

Benzinga ·  May 15 16:31

Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.04) by 500 percent. This is a 4 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $9.267 million which missed the analyst consensus estimate of $21.533 million by 56.96 percent. This is a 347.90 percent increase over sales of $2.069 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment